sb 203580 has been researched along with ketamine in 4 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (ketamine) | Trials (ketamine) | Recent Studies (post-2010) (ketamine) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 15,029 | 2,321 | 6,678 |
| Protein | Taxonomy | sb 203580 (IC50) | ketamine (IC50) |
|---|---|---|---|
| Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | 4.216 | |
| Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | 4.216 | |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | 5.02 | |
| Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | 5.02 | |
| Glutamate receptor ionotropic, NMDA 1 | Homo sapiens (human) | 3.7762 | |
| Glutamate receptor ionotropic, NMDA 2A | Homo sapiens (human) | 3.5563 | |
| Glutamate receptor ionotropic, NMDA 2B | Homo sapiens (human) | 4.1059 | |
| Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | 5.02 | |
| Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | 5.02 | |
| Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | 5.02 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kang, HS; Kim, IS; Kim, JS; Kim, NS; Kim, SJ; Kim, SZ; Kwak, YG; Lee, MY; Lee, SJ; Park, SY; Seol, JW | 1 |
| He, GN; Lu, HW; Ma, H; Wang, JK | 1 |
| Hossain, M; Liu, L; Xu, N | 1 |
| Wu, H; Zhang, L; Zhang, Z; Zhou, C | 1 |
4 other study(ies) available for sb 203580 and ketamine
| Article | Year |
|---|---|
Ketamine-induced cardiac depression is associated with increase in [Mg2+]i and activation of p38 MAP kinase and ERK 1/2 in guinea pig.
Topics: Animals; Cytoplasm; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Flavonoids; Guinea Pigs; Heart; Imidazoles; Ketamine; Magnesium; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Myocardium; p38 Mitogen-Activated Protein Kinases; Pyridines | 2006 |
Ketamine reduces inducible superoxide generation in human neutrophils in vitro by modulating the p38 mitogen-activated protein kinase (MAPK)-mediated pathway.
Topics: Analgesics; Apoptosis; Cardiotonic Agents; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Induction; Enzyme Inhibitors; Humans; Imidazoles; Isoproterenol; Ketamine; MAP Kinase Signaling System; N-Formylmethionine Leucyl-Phenylalanine; NADPH Oxidases; Neutrophils; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyridines; Superoxides | 2010 |
Pharmacological inhibition of p38 mitogen-activated protein kinases affects KC/CXCL1-induced intraluminal crawling, transendothelial migration, and chemotaxis of neutrophils in vivo.
Topics: Animals; Cells, Cultured; Chemokine CXCL1; Chemotaxis, Leukocyte; Enzyme Inhibitors; Imidazoles; Ketamine; Male; Mice; Mice, Inbred C57BL; Neutrophil Infiltration; Neutrophils; p38 Mitogen-Activated Protein Kinases; Pyridines; Transendothelial and Transepithelial Migration; Xylazine | 2013 |
Ketamine inhibits LPS-induced HGMB1 release in vitro and in vivo.
Topics: Animals; Cecum; Cell Line; Disease Models, Animal; HMGB1 Protein; Humans; Imidazoles; Ketamine; Lipopolysaccharides; Macrophages; Male; Mice; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Peritonitis; Pyridines; Rats; Rats, Sprague-Dawley; Sepsis | 2014 |